Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Markland Technologies was a homeland security and defense company that specialized in providing integrated security solutions, including advanced chemical and biological detection systems. The company's bio-defense division focused on the development of automated sensors designed to identify biological agents such as anthrax in high-risk environments like government buildings and mailrooms. During the early 2000s, the company expanded its portfolio through the acquisition of several technology firms, including EOIR Technologies and Technest Holdings. Despite its initial growth in the post-9/11 security market, the company faced significant financial difficulties and eventually ceased operations. Markland Technologies is primarily remembered for its contributions to early biosecurity and pathogen detection infrastructure.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Markland Technologies.